International Journal of Hematology and Oncology 2023, Vol 33, Num 4 Page(s): 117-124
EVALUATION OF CYTOKERATIN FRAGMENT 19 (CYFRA21-1) IN THE DIAGNOSIS OF LUNG CANCER

M. CEMİL SAVAŞ1, MUSTAFA BENEKLİ1, İBRAHİM H. GÜLLÜ1, İBRAHİM AKALIN1, M. KADRİ ALTUNDAĞ1, İBRAHİM BARIŞTA1, GÜLTEN TEKUZMAN1

Gaziantep Üniversitesi Tıp Fakültesi, Gastroenteroloji BD, GAZİANTEP

Keywords: lung cancer, cyfra21-1, cytokeratin fragment-19, tumor marker
Lung cancer is a very frequent cancer type and an important health problem over the world. Cytokeratin fragment 19 (CYFRA 21-1), a new epithelial tumor marker, is evaluated in the diagnosis and classification of subtypes of lung cancer in comparison to serum CEA levels in patients with lung cancer and healthy controls. Thirty-seven men and one woman with the diagnosis of lung cancer, a total of 38 patients were evaluated during the study. Subtypes of the disease were as follows: 17 with small cell lung cancer, 21 with non-small cell lung cancer. Age and sex matched 42 healthy persons were taken as control group. Median level of serum CYFRA 21-1 was 6.70 ng/ml (3.86-15.08) in patients with lung cancer and 2.46 ng/ml (1.80-2.90) in healthy controls. Sensitivity of CYFRA 21-1 was 81% and spesificity was 97% for diagnosis of lung cancer. Lung cancer, whereas sensitivity of CEA was 71% and spesificity was 90%. As a conclusion, serum CYFRA 21-1 can be used in the diagnosis and differantial diagnosis of lung cancer.